Loading...

Charles Hart, PhD

TitleDirector Catalyst Program
InstitutionUniversity of California San Francisco
DepartmentInnovation Ventures
Address550 16th. Street
San Francisco CA 94158
Phone415-514-8510
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brenner A, Zuniga R, Sun JD, Floyd J, Hart C, Kroll S, Fichtel L, Cavazos D, Caflisch L, Gruslova A, Lodi A, Tiziani S. Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study. Neuro Oncol. 2018 Feb 05. PMID: 29415215.
      View in: PubMed
    2. Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart C, Mitchell JB, Krishna MC. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. Antioxid Redox Signal. 2018 Jan 10; 28(2):131-140. PMID: 28741367.
      View in: PubMed
    3. Hajj C, Russell J, Hart C, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL. A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. Transl Oncol. 2017 Oct; 10(5):760-765. PMID: 28778024.
      View in: PubMed
    4. Stokes AM, Hart C, Quarles CC. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models. Tomography. 2016 Sep; 2(3):229-237. PMID: 27752544.
      View in: PubMed
    5. Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart C, Geschwind JF. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clin Cancer Res. 2017 Jan 15; 23(2):536-548. PMID: 27440271.
      View in: PubMed
    6. Yoon C, Chang KK, Lee JH, Tap WD, Hart C, Simon MC, Yoon SS. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1a inhibition, and hypoxia-activated chemotherapy. Oncotarget. 2016 Jul 12; 7(28):42844-42858. PMID: 27374091.
      View in: PubMed
    7. Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart C, Baker AF, Gillies R. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016; 11(5):e0155289. PMID: 27227903; PMCID: PMC4882075.
    8. Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart C. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. Cancer Biol Ther. 2016 04 02; 17(4):371-80. PMID: 26818215.
      View in: PubMed
    9. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart C, Andreeff M, Konopleva M. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98. PMID: 26603259; PMCID: PMC4818660 [Available on 04/01/17].
    10. Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart C. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. Am J Cancer Res. 2015; 5(7):2139-55. PMID: 26328245; PMCID: PMC4548326.
    11. Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart C. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21; 15:422. PMID: 25994202; PMCID: PMC4453293.
    12. Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, Sun JD, Hart C, Windhorst AD, van Elmpt W, Dubois LJ, Lambin P. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 01; 21(13):2984-92. PMID: 25805800.
      View in: PubMed
    13. Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart C. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015; 16(3):438-49. PMID: 25679067; PMCID: PMC4623012.
    14. Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart C, Zhang X, Leos R, Martinez GV, Baker AF, Gillies RJ. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer. PLoS One. 2014; 9(12):e113586. PMID: 25532146; PMCID: PMC4273999.
    15. Takakusagi Y, Matsumoto S, Saito K, Matsuo M, Kishimoto S, Wojtkowiak JW, DeGraff W, Kesarwala AH, Choudhuri R, Devasahayam N, Subramanian S, Munasinghe JP, Gillies RJ, Mitchell JB, Hart C, Krishna MC. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302. PLoS One. 2014; 9(9):e107995. PMID: 25254649; PMCID: PMC4177858.
    16. Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart C, Wang ES. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. Clin Cancer Res. 2013 Dec 01; 19(23):6506-19. PMID: 24088735.
      View in: PubMed
    17. Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, De Bryune E, Xu S, Van Camp B, Handisides D, Hart C, Vanderkerken K. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther. 2013 Sep; 12(9):1763-73. PMID: 23832122.
      View in: PubMed
    18. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart C, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94. PMID: 22394600; PMCID: PMC3382938.
    19. Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart C. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1487-98. PMID: 22382881; PMCID: PMC3985381.
    20. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart C. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012 Feb 01; 18(3):758-70. PMID: 22184053.
      View in: PubMed
    21. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart C. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012 Mar; 11(3):740-51. PMID: 22147748.
      View in: PubMed
    22. Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart C, Matteucci M. 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem. 2011 Mar 24; 54(6):1715-23. PMID: 21341674.
      View in: PubMed
    23. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart C, Vanderkerken K. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010 Sep 02; 116(9):1524-7. PMID: 20530289.
      View in: PubMed
    24. Smith RL, Repert DA, Hart C. Geochemistry of inorganic nitrogen in waters released from coal-bed natural gas production wells in the Powder River Basin, Wyoming. Environ Sci Technol. 2009 Apr 01; 43(7):2348-54. PMID: 19452885.
      View in: PubMed
    25. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart C, Matteucci M. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008 Apr 24; 51(8):2412-20. PMID: 18257544.
      View in: PubMed
    26. Meng F, Cai X, Duan J, Matteucci MG, Hart C. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemother Pharmacol. 2008 May; 61(6):953-63. PMID: 17639393.
      View in: PubMed
    27. Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart C. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. Anticancer Drugs. 2007 Apr; 18(4):435-45. PMID: 17351396.
      View in: PubMed
    28. Hart C. Finding the target after screening the phenotype. Drug Discov Today. 2005 Apr 01; 10(7):513-9. PMID: 15809197.
      View in: PubMed
    Charles's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _